Cefotiam therapy of lower respiratory tract infections.

Por Polis, M A, Tuazon, C U
Publicado em 1985

Transmission of Giardia lamblia from a day care center to the community.

Por Polis, M A, Tuazon, C U, Alling, D W, Talmanis, E
Publicado em 1986

Baseline CD4+ T-Cell Counts Predict HBV Viral Kinetics to Adefovir Treatment in Lamivudine-Resistant HBV-Infected Patients with or without HIV Infection

Por Cortez, K.J., Proschan, M.A., Barrett, L., Brust, D.G., Formentini, E., Davey, R.T., Masur, H., Polis, M.A., Neumann, A.U., Kottilil, S.
Publicado no HIV Clin Trials (2013)

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Por Kovacs, J A, Vasudevachari, M B, Easter, M, Davey, R T, Falloon, J, Polis, M A, Metcalf, J A, Salzman, N, Baseler, M, Smith, G E
Publicado em 1993

Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661.

Por Davey, R T, Dewar, R L, Reed, G F, Vasudevachari, M B, Polis, M A, Kovacs, J A, Falloon, J, Walker, R E, Masur, H, Haneiwich, S E
Publicado em 1993

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.

Por Cundy, K C, Petty, B G, Flaherty, J, Fisher, P E, Polis, M A, Wachsman, M, Lietman, P S, Lalezari, J P, Hitchcock, M J, Jaffe, H S
Publicado em 1995

Gene Expression Profiles Predict Emergence Of Psychiatric Adverse Events In HIV/HCV Coinfected Patients On Interferon-based HCV Therapy

Por Rasimas, J.J, Katsounas, A, Raza, H, Murphy, A.A, Yang, J, Lempicki, R.A, Osinusi, A, Masur, H, Polis, M.A, Kottilil, S, Rosenstein, D.L
Publicado em 2012

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.

Por Polis, M A, Spooner, K M, Baird, B F, Manischewitz, J F, Jaffe, H S, Fisher, P E, Falloon, J, Davey, R T, Kovacs, J A, Walker, R E
Publicado em 1995

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

Por Polis, M A, Piscitelli, S C, Vogel, S, Witebsky, F G, Conville, P S, Petty, B, Kovacs, J A, Davey, R T, Walker, R E, Falloon, J, Metcalf, J A, Craft, C, Lane, H C, Masur, H
Publicado em 1997

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Por Davey, R T, Chaitt, D G, Reed, G F, Freimuth, W W, Herpin, B R, Metcalf, J A, Eastman, P S, Falloon, J, Kovacs, J A, Polis, M A, Walker, R E, Masur, H, Boyle, J, Coleman, S, Cox, S R, Wathen, L, Daenzer, C L, Lane, H C
Publicado em 1996

Clinical characteristics of non-tuberculous mycobacterial pulmonary infections in Bamako, Mali

Por Kone, B., Sarro, Y. S., Maiga, M., Sanogo, M., Somboro, A. M., Diarra, B., Togo, A. C. G., Coulibaly, N., Dembele, B. P. P., Goita, D., Baya, B., Kone, A., Diabaté, S., Polis, M. A., Belson, M., Dao, S., Orsega, S., Achenbach, C. J., Murphy, R. L., Diallo, S., Siddiqui, S.
Publicado no Epidemiol Infect (2018)

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014

Por Diarra, B., Goita, D., Tounkara, S., Sanogo, M., Baya, B., Togo, A. C. G., Maiga, M., Sarro, Y. S., Kone, A., Kone, B., M’Baye, O., Coulibaly, N., Kassambara, H., Cisse, A., Belson, M., Polis, M. A., Otu, J., Gehre, F., Antonio, M., Dao, S., Siddiqui, S., Murphy, R. L., de Jong, B. C., Diallo, S.
Publicado no BMC Infect Dis (2016)